InMed Pharmaceuticals (INM) Invested Capital (2019 - 2026)
InMed Pharmaceuticals has reported Invested Capital over the past 5 years, most recently at $9.6 million for Q4 2025.
- For Q4 2025, Invested Capital rose 55.09% year-over-year to $9.6 million; the TTM value through Dec 2025 reached $9.6 million, up 55.09%, while the annual FY2025 figure was $13.4 million, 45.93% up from the prior year.
- Invested Capital for Q4 2025 was $9.6 million at InMed Pharmaceuticals, down from $11.6 million in the prior quarter.
- Over five years, Invested Capital peaked at $15.2 million in Q3 2021 and troughed at -$9.6 million in Q3 2023.
- A 5-year average of $9.8 million and a median of $11.0 million in 2022 define the central range for Invested Capital.
- Biggest five-year swings in Invested Capital: plummeted 187.01% in 2023 and later surged 187.65% in 2024.
- Year by year, Invested Capital stood at $14.2 million in 2021, then rose by 0.77% to $14.3 million in 2022, then decreased by 10.9% to $12.8 million in 2023, then plummeted by 51.6% to $6.2 million in 2024, then surged by 55.09% to $9.6 million in 2025.
- Business Quant data shows Invested Capital for INM at $9.6 million in Q4 2025, $11.6 million in Q3 2025, and $13.4 million in Q2 2025.